Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Atezolizumab in combination with bevacizumab for advanced renal cell carcinoma – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Atezolizumab is a new drug to treat advanced renal cell carcinoma. Renal cell carcinoma is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Atezolizumab is delivered straight into the blood and works by altering the body's immune reaction to the cancer. Some studies have shown that atezolizumab may work best in combination with bevacizumab and may offer a new treatment option for patients with untreated advanced renal cell carcinoma. Indexing Status Subject indexing assigned by CRD MeSH Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016001024 Date abstract record published 11/10/2016 |
